This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Healthcare ETFs Gain on Rising Demand for COVID-19 Tests
by Sweta Jaiswal, FRM
A growing demand for COVID-19 tests has indulged major healthcare place in the race to develop competent testing kits.
Abbott (ABT) in Focus: Stock Moves 6.4% Higher
by Zacks Equity Research
Abbott (ABT) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Abbott (ABT) Rides on Point-of-Care Coronavirus Test Launch
by Zacks Equity Research
Abbott (ABT) launches a portable molecular point-of-care test to speed up coronavirus detection, especially in areas with severe outbreaks.
Here's Why You Should Hold on to Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) on its strong segmental results in the fourth quarter of 2019.
Stock Market News for Mar 31, 2020
by Zacks Equity Research
Benchmarks gained on Monday, boosted by healthcare companies that are trying their best to bring the pandemic to a halt.
4 MedTech Stocks Set to Rebound Post Coronavirus-Led Crisis
by Zacks Equity Research
Here are some MedTech stocks which are steadily inching toward a trend reversal after registering record declines over the past few weeks.
Luminex (LMNX) Receives EUA for Coronavirus Detection Test
by Zacks Equity Research
Luminex (LMNX) receives EUA for its NxTAG CoV Extended Panel that will be used to detect the SARS-CoV-2 virus.
4 Stocks Countering Coronavirus Battle With Testing Kits
by Urmimala Biswas
While the market bloodbath is showing no signs of dissipating any time soon, investors might keep an eye on certain genetic testing and medical device companies.
FDA EUA for Coronavirus Tests Boosts MedTech: 3 Stocks in Focus (Revised)
by Sriparna Ghosal
These key biotech and molecular diagnostic players banking on the receipt of FDA's EUA for COVID-19 tests are currently outperforming the broader industries they belong to.
FDA EUA for Coronavirus Tests Boosts MedTech: 3 Stocks in Focus
by Sriparna Ghosal
These key biotech and molecular diagnostic players banking on the receipt of FDA's EUA for COVID-19 tests are currently outperforming the broader industries they belong to.
Bull of the Day: Edwards Lifesciences (EW)
by Kevin Cook
While most elective procedures are being deferred, the innovator of minimally-invasive heart valve replacement beats on
HRC vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRC vs. ABT: Which Stock Is the Better Value Option?
PerkinElmer (PKI) Receives EUA for Coronavirus Detection Test
by Zacks Equity Research
PerkinElmer (PKI) introduces test for the detection of coronavirus after it receives EUA for the same.
OPKO's BioReference Laboratories Widens COVID-19 Testing (Revised)
by Zacks Equity Research
OPKO's (OPK) subsidiary, BioReference Laboratories, collaborates with the City of Detroit to offer COVID-19 testing.
OPKO's BioReference Laboratories Widens COVID-19 Testing
by Zacks Equity Research
OPKO's (OPK) subsidiary, BioReference Laboratories, collaborates with the City of Detroit to offer COVID-19 testing.
Abbott Launches Coronavirus Detection Test After FDA Gives EUA
by Zacks Equity Research
Abbott (ABT) launches test for the detection of coronavirus in human, after receiving the EUA.
Abbott (ABT) Stock Moves -0.29%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $79.26 in the latest trading session, marking a -0.29% move from the prior day.
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific and Abbott Laboratories
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific and Abbott Laboratories
Coronavirus Ails S&P 500 Index, MedTechs Bear the Brunt
by Urmimala Biswas
S&P 500 MedTech stocks pull the index further down on COVID-19 situation becoming grimmer.
HRC vs. ABT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HRC vs. ABT: Which Stock Is the Better Value Option?
Neovasc (NVCN) Releases Update on Reducer and Tiara Products
by Zacks Equity Research
Neovasc (NVCN) expects an approval from the FDA for Reducer by end of 2020.
Abbott (ABT) Stock Moves -1.91%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $80.52 in the latest trading session, marking a -1.91% move from the prior day.
Coronavirus Spreads Rapidly Worldwide: Medtech Stocks in Focus
by Aparajita Dutta
The coronavirus outbreak disrupts manufacturing and supply chain in China, which in turn might have taken a toll on U.S. Medtech stocks.
The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher
Medical Products Industry Outlook: Growth Prospects Bright
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, courtesy of AI, Medical Mechatronics and Robotics and growing R&D expenditure.